A pharmacokinetic-pharmacodynamic model for neuromuscular blocking agents to predict train-of-four twitches

被引:2
|
作者
Eleveld, DJ [1 ]
De Haes, A [1 ]
Proost, JH [1 ]
Wierda, JMKH [1 ]
机构
[1] Res Grp Expt Anesthesiol & Clin Pharmacol, NL-9700 RB Groningen, Netherlands
关键词
neuromuscular relaxants; pharmacokinetics; models; computers; train-of-four stimulation;
D O I
10.1023/A:1024430413262
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The train-of-four (TOF) stimulation pattern consists of 4 stimuli (T1, T2, T3, and T4) at 2 Hz, and is used in daily anesthesiological practice to determine the degree of relaxation caused by muscle relaxants. At a surgical levels of relaxation the degree of relaxation can be estimated by counting the number of "measurable'' or "visible'' muscular reactions to the 4 stimuli in the TOF stimulation pattern (TOF count). During recovery relaxation can be estimated by calculating the TOF ratio (T4/T1). Bartkowski and Epstein described a pharmacokinetic-pharmacodynamic (PK-PD) model to predict TOF ratio by modifying and extending the PK-PD model as described by Sheiner to use a hypothetical distributed effect compartment described by a median equilibration rate constant and a dispersion parameter. We extended the Bartkowski and Epstein PK-PD model to simulate all four TOF twitches by including EC50 terms for T2 and T3. We fit this model to data from the pig and compared the results to fitted models using separate PD models for each TOF twitch ( extended Sheiner model). The extended Bartkowski and Epstein model fit the twitch height data from all four TOF twitches better than the extended Sheiner model and has fewer parameters.
引用
收藏
页码:105 / 118
页数:14
相关论文
共 50 条
  • [41] A Population Pharmacokinetic-Pharmacodynamic Model for Allopurinol in Patients with Gout
    Wright, Daniel F. B.
    Duffull, Stephen B.
    Merriman, Tony R.
    Barclay, Murray L.
    Stamp, Lisa K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S33 - S33
  • [42] Accuracy of train-of-four assessment for ICU patients receiving continuous neuromuscular blockade
    Devlin, JW
    Coplin, WM
    Swarczinski, C
    Leacock, RO
    Lewis, RA
    Kruse, JA
    CRITICAL CARE MEDICINE, 1999, 27 (12) : A72 - A72
  • [43] Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model
    Lozano, Roberto
    Domeque, Nieves
    Apesteguia, Alberto-Fermin
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 153 - 159
  • [44] The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution
    Witzany, Christopher
    Rolff, Jens
    Regoes, Roland R.
    Igler, Claudia
    MICROBIOLOGY-SGM, 2023, 169 (07):
  • [45] Effective dose 50 of sugammadex required to reverse neuromuscular block at a train-of-four count of four
    Valsamidis, D.
    Tsekoura, V.
    Loukeri, A.
    Diakaki, A.
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2010, 27 (01) : 151 - 151
  • [46] Comparison of a new piezoelectric train-of-four neuromuscular monitor, the ParaGraph, and the Relaxometer mechanomyograph
    Dahaba, AA
    Von Klobucar, F
    Rehak, PH
    List, WF
    BRITISH JOURNAL OF ANAESTHESIA, 1999, 82 (05) : 780 - 782
  • [47] Pharmacokinetic aspects of the onset of action of neuromuscular blocking agents
    Proost, JH
    Wierda, JMKH
    ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2000, 35 (02): : 98 - 100
  • [48] THE IMPORTANCE OF PHARMACOKINETIC-PHARMACODYNAMIC SURROGATE MARKERS TO OUTCOME - FOCUS ON ANTIBACTERIAL AGENTS
    HYATT, JM
    MCKINNON, PS
    ZIMMER, GS
    SCHENTAG, JJ
    CLINICAL PHARMACOKINETICS, 1995, 28 (02) : 143 - 160
  • [49] Clinical pharmacokinetic-pharmacodynamic analyses: a critical element for developing antibacterial agents
    Bhavnani, Sujata M.
    Hammel, Jeffrey P.
    CURRENT OPINION IN PHARMACOLOGY, 2017, 36 : 124 - 129
  • [50] COMBINED PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODEL TO PREDICT METHEMOGLOBIN FORMATION BY A NEW CANDIDATE ANTIMALARIAL
    BRUECKNER, RP
    FLECKENSTEIN, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (02) : 156 - 156